Modeling Parkinson’s disease pathology by combined injection of fibrilar and monomeric α-synuclein in rat brain
Objective: Development of a fast and progressive Parkinson’s disease (PD) model in rat Background: α-Synuclein is a common link between sporadic and familial PD. Rodent…Antibody binding differences in alpha-synuclein from Parkinson’s disease and multiple system atrophy
Objective: Determine whether alpha-synuclein derived from Parkinson's disease (PD) and multiple system atrophy (MSA) brains has different conformations as defined by biochemical and antibody-based approaches. Background: There…Full sequencing and GWAS markers analysis of SNCA in RBD and progression to synucleinopathies.
Objective: To study the role of SNCA variants in REM sleep Behavior Disorder (RBD) and progression to synucleinopathies. Background: Individuals with properly diagnosed idiopathic RBD…Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration
Objective: To determine the relationship between synucleinopathy, neuroinflammation and nigrostriatal degeneration using the rat α-syn PFF model. Background: No therapy exists to halt or slow…In silico predictive analytics: accelerating identification of potential disease-modifying compounds for Parkinson’s disease
Objective: To use an in silico screen to identify compounds that have potential to reduce α-synuclein (aSyn) oligomers and are amenable to drug repurposing for…CSF, plasma and saliva alpha-Synuclein in moderately advanced Parkinson’s disease cohort: the BioFIND study
Objective: To test if alpha-synuclein (α-syn) levels in CSF, plasma and saliva predict PD status in the BioFind cohort, and to test whether α-syn levels…Alpha-synuclein enhances histone H3 lysine-9 dimethylation
Objective: To explore the nuclear function of alpha-synuclein (αS). Background: αS is a protein linked to Parkinson’s disease (PD) and related neurodegenerative disorders. It is…Salivary Alpha-Synuclein in Aging
Objective: We measured alpha-synuclein total (a-syntotal) and alpha-synuclein oligomers (a-synolig) concentration in 70 healthy subjects, of different ages (from 18 to 88 years old) to…Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia
Objective: This is a retrospective biomarker study of an open-label clinical study to examine the safety and efficacy of lower doses (<50% of CML dose)…Extracellular alpha-synuclein internalizes into cells by hijacking endocytic trafficking of dopamine transporter
Objective: The main purposes of this study were to: 1) investigate the possible effect of extracellular alpha-synuclein (aSYN) on the endocytic rate of dopamine transporter…
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 70
- Next Page »